Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
⏰ React to the Market Faster with Custom, Real-Time News Get Started
FDA advisers back Pfizer's COVID treatment for full approval
© Reuters. FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/
By Leroy Leo and Khushi Mandowara
(Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday overwhelmingly backed full approval of Pfizer (NYSE:PFE)'s oral antiviral COVID-19 treatment Paxlovid for adults at high risk of progression to severe disease.
The FDA's panel of outside experts voted 16-to-1 in favor of the drug's benefits outweighing its risk for some adults with mild-to-moderate COVID-19.
The agency is expected to make a formal approval decision by May and typically follows the advice of its expert advisers, but is not required to do so.
A full approval will eventually allow Pfizer to sell Paxlovid - which consists of two drugs in pill form - at market rates on the private market in the U.S., rather than through government contracts as it has been thus far.
Pfizer has sold the U.S. government nearly 24 million courses of Paxlovid at around $530 a course. As of March 12, the U.S. had distributed about 12.7 million courses and more than 8.5 million have been dispensed, according to government data.
A full approval also would provide doctors more flexibility in prescribing the drug and also allow the company to expand its advertising campaign.
Thursday's positive vote came after the FDA and Pfizer provided data assuaging concerns about the potential for a rebound in COVID symptoms after a five-day course of treatment.
Numerous anecdotal reports of a return of symptoms following Paxlovid treatment, including in high profile patients such as President Joe Biden and Dr. Anthony Fauci, had raised concerns.
Several panel members said they were reassured by the data presented on the COVID rebound issue.
Paxlovid has been authorized for emergency use in the U.S. in mild-to-moderate COVID patients aged 12 years and older since late 2021, but Pfizer's application for full approval only covers high-risk adults.
The FDA earlier on Thursday said the current Paxlovid emergency use authorization (EUA) for high-risk adolescents will continue to remain in effect even if it receives full approval for use in older patients.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.